Risk assessment for occult malignancy in the prostate before radical cystectomy

John C. Kefer, Bryan B. Voelzke, Robert C. Flanigan, Eva M. Wojcik, W Waters, Steven C. Campbell

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objectives. To assess our clinical ability to predict prostate involvement by transitional cell carcinoma (PI-TCC) or occult prostate cancer (CAP) in patients undergoing radical cystectomy (RCx). Methods. We retrospectively analyzed 70 male patients undergoing RCx for TCC of the bladder between 1995 and 2003, focusing on preoperative factors to predict PI-TCC or CAP. Results. Of 70 RCx patients, 30 (43%) had PI-TCC (14) or CAP (16). Risk factors for PI-TCC included carcinoma in situ, multifocal TCC, and bladder neck involvement (P <0.05 for all three analyses). All 14 patients with PI-TCC had one or more risk factors, and none of 40 patients without these risk factors had PI-TCC (P <0.001). Risk factors for CAP included elevated prostate-specific antigen level, abnormal results on digital rectal examination, and age more than 65 years. Of 16 patients with CAP, 14 had one or more of these risk factors (P <0.05). Sixteen of the seventy patients in this series (22.9%) had no risk factors for PI-TCC or CAP, and none of these had prostatic involvement with either malignancy (P <0.05). Conclusions. Our findings suggest that a well-defined subset of patients undergoing RCx might be at low risk for malignancy in the prostate. However, further evaluation of these risk factors in a prospective setting will be required to substantiate these findings and guide clinical decision making in this controversial field.

Original languageEnglish (US)
Pages (from-to)1251-1255
Number of pages5
JournalUrology
Volume66
Issue number6
DOIs
StatePublished - Dec 1 2005

Fingerprint

Cystectomy
Transitional Cell Carcinoma
Prostate
Neoplasms
Urinary Bladder
Digital Rectal Examination
Carcinoma in Situ
Prostate-Specific Antigen
Prostatic Neoplasms

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Kefer, J. C., Voelzke, B. B., Flanigan, R. C., Wojcik, E. M., Waters, W., & Campbell, S. C. (2005). Risk assessment for occult malignancy in the prostate before radical cystectomy. Urology, 66(6), 1251-1255. https://doi.org/10.1016/j.urology.2005.07.006

Risk assessment for occult malignancy in the prostate before radical cystectomy. / Kefer, John C.; Voelzke, Bryan B.; Flanigan, Robert C.; Wojcik, Eva M.; Waters, W; Campbell, Steven C.

In: Urology, Vol. 66, No. 6, 01.12.2005, p. 1251-1255.

Research output: Contribution to journalArticle

Kefer, JC, Voelzke, BB, Flanigan, RC, Wojcik, EM, Waters, W & Campbell, SC 2005, 'Risk assessment for occult malignancy in the prostate before radical cystectomy', Urology, vol. 66, no. 6, pp. 1251-1255. https://doi.org/10.1016/j.urology.2005.07.006
Kefer, John C. ; Voelzke, Bryan B. ; Flanigan, Robert C. ; Wojcik, Eva M. ; Waters, W ; Campbell, Steven C. / Risk assessment for occult malignancy in the prostate before radical cystectomy. In: Urology. 2005 ; Vol. 66, No. 6. pp. 1251-1255.
@article{cd09932ad1bf4c169a8591f04035007c,
title = "Risk assessment for occult malignancy in the prostate before radical cystectomy",
abstract = "Objectives. To assess our clinical ability to predict prostate involvement by transitional cell carcinoma (PI-TCC) or occult prostate cancer (CAP) in patients undergoing radical cystectomy (RCx). Methods. We retrospectively analyzed 70 male patients undergoing RCx for TCC of the bladder between 1995 and 2003, focusing on preoperative factors to predict PI-TCC or CAP. Results. Of 70 RCx patients, 30 (43{\%}) had PI-TCC (14) or CAP (16). Risk factors for PI-TCC included carcinoma in situ, multifocal TCC, and bladder neck involvement (P <0.05 for all three analyses). All 14 patients with PI-TCC had one or more risk factors, and none of 40 patients without these risk factors had PI-TCC (P <0.001). Risk factors for CAP included elevated prostate-specific antigen level, abnormal results on digital rectal examination, and age more than 65 years. Of 16 patients with CAP, 14 had one or more of these risk factors (P <0.05). Sixteen of the seventy patients in this series (22.9{\%}) had no risk factors for PI-TCC or CAP, and none of these had prostatic involvement with either malignancy (P <0.05). Conclusions. Our findings suggest that a well-defined subset of patients undergoing RCx might be at low risk for malignancy in the prostate. However, further evaluation of these risk factors in a prospective setting will be required to substantiate these findings and guide clinical decision making in this controversial field.",
author = "Kefer, {John C.} and Voelzke, {Bryan B.} and Flanigan, {Robert C.} and Wojcik, {Eva M.} and W Waters and Campbell, {Steven C.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/j.urology.2005.07.006",
language = "English (US)",
volume = "66",
pages = "1251--1255",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Risk assessment for occult malignancy in the prostate before radical cystectomy

AU - Kefer, John C.

AU - Voelzke, Bryan B.

AU - Flanigan, Robert C.

AU - Wojcik, Eva M.

AU - Waters, W

AU - Campbell, Steven C.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Objectives. To assess our clinical ability to predict prostate involvement by transitional cell carcinoma (PI-TCC) or occult prostate cancer (CAP) in patients undergoing radical cystectomy (RCx). Methods. We retrospectively analyzed 70 male patients undergoing RCx for TCC of the bladder between 1995 and 2003, focusing on preoperative factors to predict PI-TCC or CAP. Results. Of 70 RCx patients, 30 (43%) had PI-TCC (14) or CAP (16). Risk factors for PI-TCC included carcinoma in situ, multifocal TCC, and bladder neck involvement (P <0.05 for all three analyses). All 14 patients with PI-TCC had one or more risk factors, and none of 40 patients without these risk factors had PI-TCC (P <0.001). Risk factors for CAP included elevated prostate-specific antigen level, abnormal results on digital rectal examination, and age more than 65 years. Of 16 patients with CAP, 14 had one or more of these risk factors (P <0.05). Sixteen of the seventy patients in this series (22.9%) had no risk factors for PI-TCC or CAP, and none of these had prostatic involvement with either malignancy (P <0.05). Conclusions. Our findings suggest that a well-defined subset of patients undergoing RCx might be at low risk for malignancy in the prostate. However, further evaluation of these risk factors in a prospective setting will be required to substantiate these findings and guide clinical decision making in this controversial field.

AB - Objectives. To assess our clinical ability to predict prostate involvement by transitional cell carcinoma (PI-TCC) or occult prostate cancer (CAP) in patients undergoing radical cystectomy (RCx). Methods. We retrospectively analyzed 70 male patients undergoing RCx for TCC of the bladder between 1995 and 2003, focusing on preoperative factors to predict PI-TCC or CAP. Results. Of 70 RCx patients, 30 (43%) had PI-TCC (14) or CAP (16). Risk factors for PI-TCC included carcinoma in situ, multifocal TCC, and bladder neck involvement (P <0.05 for all three analyses). All 14 patients with PI-TCC had one or more risk factors, and none of 40 patients without these risk factors had PI-TCC (P <0.001). Risk factors for CAP included elevated prostate-specific antigen level, abnormal results on digital rectal examination, and age more than 65 years. Of 16 patients with CAP, 14 had one or more of these risk factors (P <0.05). Sixteen of the seventy patients in this series (22.9%) had no risk factors for PI-TCC or CAP, and none of these had prostatic involvement with either malignancy (P <0.05). Conclusions. Our findings suggest that a well-defined subset of patients undergoing RCx might be at low risk for malignancy in the prostate. However, further evaluation of these risk factors in a prospective setting will be required to substantiate these findings and guide clinical decision making in this controversial field.

UR - http://www.scopus.com/inward/record.url?scp=29144432745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144432745&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.07.006

DO - 10.1016/j.urology.2005.07.006

M3 - Article

VL - 66

SP - 1251

EP - 1255

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -